Search Within

Ezra Y Rosen

Formats
  1. Meeting Abstract (27)
  2. Journal Article (19)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Medicine (49)
  2. Early Drug Development Service (49)
  3. Solid Tumor Oncology Division (49)
  4. Weinberg Fellows (49)
  5. GSK Faculty (26)
  6. Department of Pathology and Laboratory Medicine (25)

More Groups

People
  1. Alexander Drilon (22)
  2. Alison Schram (12)
  3. Marc Ladanyi (11)
  4. David Hyman (10)
  5. Mark Donoghue (9)
  6. Michael Berger (9)

More People

Years
  1. 2025 (1)
  2. 2024 (11)
  3. 2023 (10)
  4. 2022 (13)
  5. 2021 (4)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (9)
  3. Clinical Cancer Research (7)
  4. Cancer Research (4)
  5. JCO Precision Oncology (2)
  6. JNCI: Journal of the National Cancer Institute (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (15)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (11)
  4. Nature Publishing Group (4)
  5. Elsevier Inc. (2)
  6. American Medical Association (1)

More Publishers

Results (49)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Camonsertib in DNA damage response-deficient advanced solid tumors: Phase 1 trial results
    Journal Article

    Yap, T. A.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; Plummer, R.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial
    Journal Article

    Schram, A. M.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, T. M.; Jin, N.; Ulahannan, S. V.; more...
    JAMA Oncology (2023)

    Fulltext@MSK | Save
  • OncoKB, MSK's precision oncology knowledge base
    Meeting Abstract

    Suehnholz, S. P.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; Ladanyi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Precision oncology: 2022 in review
    Review

    Rosen, E.; Drilon, A.; Chakravarty, D.
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
    Meeting Abstract

    Rosen, E.; Silverman, I. M.; Fontana, E.; Lee, E. K.; Spigel, D. R.; Højgaard, M.; Lheureux, S.; Mettu, N. B.; Carneiro, B. A.; Carter, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors
    Meeting Abstract

    Meric-Bernstam, F.; Sharma, M.; Sommerhalder, D.; Skeel, R. T.; El-Khoueiry, A. B.; Caswell-Jin, J. L.; Patel, P. H.; Rosen, E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Preliminary results from FLAGSHP-1: A phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    Meeting Abstract

    McKean, M.; Barve, M.; Hong, D.; Parikh, A.; Rosen, E.; Yang, J.; Picard, R.; Yi, J.; Brail, L.; Vecchio, D.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save